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BACKGROUND: To develop targeted and tailored inter-
ventions for addressing medication non-adherence, it is
important to identify underlying factors.
OBJECTIVE: To identify factors associated with non-
adherence as well as subtypes of non-adherence to anti-
hypertensive or antihyperlipidemic drugs among patients
with type 2 diabetes in Indonesia.
DESIGN: An observational multicenter cross-sectional
survey.
PARTICIPANTS: Patients with type 2 diabetes using ei-
ther antihypertensive or antihyperlipidemic drugs in four
regions in Indonesia.
MAIN MEASURES: Non-adherence and its subtypes of
intentional and unintentional non-adherence were
assessed using the Medication Adherence Report Scale.
Necessity and concern beliefs were assessed with the Be-
liefs about Medicines Questionnaire. We applied binary
andmultinomial logistic regression to assess associations
of medication beliefs, sociodemographic factors, and
clinical-related factors to non-adherence and report odds
ratios (OR) with 95% confidence intervals (CI).
KEY RESULTS: Of 571 participating patients (response
rate 97%), 45.5% and 52.7% were non-adherent to anti-
hypertensive and antihyperlipidemic drugs, respectively.
Older age was associated with non-adherence to antihy-
pertensive drugs (60–69 years) (OR, 5.65; 95% CI, 2.68–
11.92), while higher necessity beliefs (OR, 0.92; 95% CI,
0.88–0.95) were associatedwith less non-adherence. Fac-
tors associatedwith non-adherence to antihyperlipidemic
drugs were female gender (OR, 1.84; 95% CI, 1.03–3.27)
and higher concern beliefs (OR, 1.10; 95% CI, 1.03–1.18),
while higher necessity beliefs (OR, 0.89; 95% CI, 0.83–
0.96) were associated with less non-adherence.
CONCLUSIONS: The main factors associated with non-
adherence to antihypertensive and antihyperlipidemic
drugs are modifiable. In general, beliefs about the neces-
sity of the drug are important but for antihyperlipidemic
drugs concerns are important as well. Healthcare pro-
viders should pay attention to identify and address med-
ication beliefs during patient counselling.
KEY WORDS: medication non-adherence; medication beliefs; diabetes
mellitus; blood pressure–lowering medication; lipid-lowering medication.
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INTRODUCTION
Diabetes is an emerging chronic disease in developing coun-
tries, including Indonesia.1 The number of patients with dia-
betes in Indonesia was 10.3 million in 2017, and this number
is expected to increase to 16.7 million by 2045.2 Patients with
diabetes have a higher prevalence rate of cardiovascular dis-
ease (CVD) than adults without diabetes,3 which is a major
cause of comorbidity and mortality.4 Hypertension and hyper-
lipidemia are common in patients with diabetes and contribute
significantly to an increased risk of CVD.5 Therefore, antihy-
pertensive and antihyperlipidemic co-medication is often nec-
essary in diabetes patients.5
Although antihypertensive and antihyperlipidemic drugs are
fully covered by health insurance in Indonesia, medication ad-
herence to these drugs is known to be suboptimal,6 which may
lead to poor health outcomes and increased healthcare costs.7 The
risk of non-adherence to antihypertensive and antihyperlipidemic
drugs is high due to the asymptomatic nature of these diseases,
that is, the lack of noticeable efficacy by the patient in everyday
life.8, 9 Patients with diabetes may have particular problems with
their adherence to antihypertensive and antihyperlipidemic co-
medication. While much research has been conducted to assess
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adherence to their antidiabetic drugs and its underlying factors,10,
11 there is limited knowledge regarding their adherence to car-
diovascular co-medication.
In Indonesia, the guidelines emphasize the importance of
addressing medication adherence during patient counselling in
the pharmacy,12 community health center (CHC),13 and hos-
pital.14 However, there is no clear evidence of which informa-
tion or focus is needed to improve medication adherence.
Several studies have identified possible factors associated with
medication non-adherence among patients with diabetes in
developed15, 16 and developing countries.17 However, these
studies have explored largely non-modifiable factors with a
weak association between most sociodemographic or drug-
related factors and medication non-adherence. In other set-
tings, medication beliefs were found to be one of the important
modifiable factors associated with intentional (a conscious
decision after balancing the pros and cons of a medication)
and unintentional (lack of understanding or forgetfulness)
non-adherence.18–22 Medication beliefs in general among pa-
tients in Asia23 and in particular to cardiovascular drugs in
Indonesia21 were reported low. The Necessity–Concern
Framework emphasizes that medication beliefs consist of the
necessity of drugs based on beliefs about the positive effects
and concerns about the adverse consequences of taking a
drug.24 A meta-analytic review using this framework includ-
ing patients with diabetes in developed countries showed that
stronger beliefs of necessity and fewer concerns about treat-
ment were associated with higher adherence.25
Although results are not fully consistent, it seems that
unintentional and intentional non-adherence can differ among
the therapeutics groups as reported by patients.26, 27 Particu-
larly, differences in concerns may be associated with differ-
ences in intentional non-adherence, whereas difference in
numbers of drugs needed per indication may be associated
with difference in unintentional non-adherence.26, 27 To de-
velop a targeted and tailored intervention, insight into the
relation between necessity and concern beliefs and non-
adherence to antihypertensive and antihyperlipidemic drugs
among patients with type 2 diabetes in Indonesia is needed.
The primary objective of this study is to identify factors
associated with non-adherence to antihypertensive and
antihyperlipidemic drugs among patients with type 2 diabetes
in Indonesia with a focus on medication beliefs. The second-
ary objective is to identify factors associated with different
subtypes of non-adherence to antihypertensive and
antihyperlipidemic drugs among these patients.
METHODS
Study Design, Setting, and Recruitment of
Patients
We conducted an observational multicenter cross-sectional
survey among patients with type 2 diabetes in four regions in
Indonesia (Bandung City, Makassar City, Samarinda City, and
Yogyakarta City). In each region, at least five community
health centers (CHCs), locally called puskesmas, were select-
ed as sampling sites. CHCs are primary healthcare centers at
the subdistrict level, with each center staffed with medical
doctors, nurses, midwives, and pharmacists. The CHCs were
purposively selected based on a sufficient number of diabetes
patients with hypertension and/or hyperlipidemia.
We collected data from October 2018 to March 2019 from
patients who met the following inclusion criteria: aged over
18 years, with a diagnosis of type 2 diabetes at least 1 year,
were prescribed antihypertensive and/or antihyperlipidemic
drugs for at least 3 months (prevalent users), and were literate.
We excluded patients who had their medication picked up by
someone else. The Health Research Ethics Committee of
Universitas Padjadjaran approved the study protocol (no.
1137/UN6.KEP/EC/2018).
Outcomes
Adherence was assessed using the Medication Adherence
Report Scale (MARS), which has shown to perform well on
a number of psychometric indicators and internal-reliability.28
The MARS has been translated and validated to Indonesian
and showed to be valid and reliable.29 The MARS contains
one item that reflects unintentional non-adherence (“I forget to
take my lipid-lowering medicines”) and four items that largely
reflect different forms of intentional non-adherence (e.g., “I
alter the dose of my lipid-lowering medicines”).28 Patients
indicate how often each item applied to them in the last
3 months on a 5-point Likert scale, where 5, “never”; 4,
“rarely”; 3, “sometimes”; 2, “often” and 1, “always”.28 Non-
adherence is defined as a score of 1 to 3 on any of the items,
and adherence as a score of 4 or 5 on all items allowing for
rarely missing or changing a dose. We defined the subtypes of
non-adherence a priori as follows:
1. Unintentional non-adherence includes patients who
report to be non-adherent on unintentional adherence
(score 1–3 for item 1) but adherent on all intentional
non-adherence items (score 4–5 for items 2–5).
2. Intentional non-adherence includes patients who report
some form of intentional non-adherence (score 1–3 for at
least one of the items 2–5) but adherent on the
unintentional non-adherence item (score 4–5 for item 1).
3. In part intentional non-adherence includes patients who
report some form of non-adherence on intentional (score
1–3 for at least one of the items 2–5) and on unintentional
non-adherence items (score 1–3 for item 1).
Potential Factors Associated with Non-
adherence
Patients’ beliefs were assessed using Beliefs about Medicines
Questionnaire (BMQ)-specific.24 The Indonesian version of
the BMQ-specific showed to be valid (correlation value of
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each question to the total score > 0.530) and reliable
(Cronbach α coefficient of 0.835 and 0.811 for necessity and
concern beliefs, respectively) (unpublished manuscript). The
BMQ-specific contains five items about necessity beliefs (e.g.,
“My health at present depends on my lipid-lowering medi-
cines”), five items about concern beliefs (e.g., “I sometimes
worry about becoming too dependent on my lipid-lowering
medicines”), and one item about side effects (e.g., “My lipid-
lowering medicines gives me unpleasant side effects”). Pa-
tients indicate how often each item applied to them in the last
3 months on a 5-point Likert scale ranging from “strongly
disagree” to “strongly agree” with an overall range from 5
(low necessity, low concern) to 25 (high necessity, high con-
cern). We calculated the necessity–concern differential score
by subtracting the scores of the concerns scale from the
necessity scale (range − 20 to 20). A positive differential score
indicates stronger beliefs in the necessity, while a negative
score indicates stronger concern.24 The item about experi-
enced side effects was included because of its expected addi-
tional role in non-adherence.30, 31
Sociodemographic factors included as non-modifiable fac-
tors were age at the completion of the questionnaire, gender,
highest level of education completed (no formal education/
elementary school, junior high school, senior high school, or
university), and type of health insurance. Type of health in-
surance was classified as those whose insurance premium was
paid by the government (BPJS-PBI), those whose insurance
premium was paid by the patients themselves (BPJS-Non
PBI), or those without health insurance. Clinical factors in-
cluded as non-modifiable factors were obtained from medical
records: time since diagnosis of diabetes, hypertension, and/or
hyperlipidemia (years) and the most recent systolic blood
pressure (SBP), diastolic blood pressure (DBP), and total
cholesterol level in the past 3 months.
Data Collection
The pharmacist on duty at the CHCs screened the patients’
eligibility. Once a patient was deemed eligible, the pharmacist
informed the researcher or research assistant to approach the
patient and explain the study, and ask to sign informed con-
sent. Consenting patients were asked to report the name of
their antihypertensive or antihyperlipidemic drugs and subse-
quently filled in the MARS and BMQ-specific questionnaire.
If patients used both antihypertensive and antihyperlipidemic
drugs, the MARS and BMQ-specific questionnaires were
administered for each therapeutic group. Patients were asked
to complete the questionnaire independently. However, in
some cases, elderly patients were allowed to complete the
questionnaire verbally. Research assistants collected all other
data from the medical records using a predefined data collec-
tion form. For those with incomplete or unavailable medical
records, diagnostic data were obtained using patients printed
record from the private laboratory they had visited.
Sample Size Calculation
A previous small-scale study showed that non-adherence
rates among Indonesian patients with diabetes ranged
from 50 to 65% using the MARS questionnaire.32 In
studies elsewhere, similar and lower non-adherence rates
have been found, also using the MARS questionnaire.26,
33 Therefore, a minimum sample size of 180 patients per
therapeutic drug group was required based on the for-
mula for prediction models with a binary outcome,34
when including maximum of 9 possible independent
variables in the multivariate analysis and assuming a
proportion of non-adherence of 50%. With an expected
distribution of 2:1 between patients receiving antihyper-
tensive drugs and antihyperlipidemic drugs, 540 patients
need to be recruited in the most conservative scenario of
no overlap in the use of both therapeutic groups.
Data Analysis
Analyses were conducted per therapeutic group. When a
p a t i e n t u s e d b o t h a n t i h y p e r t e n s i v e a n d
antihyperlipidemic drugs, they were included for both
therapeutic groups. Clinical factors related to hyperten-
sion or hyperlipidemia, such as duration of hypertension
and/or hyperlipidemia and the most recent SBP, DBP, or
total cholesterol level, were included only for the related
therapeutic group. Descriptive statistics were used to
summarize the patient characteristics. Pearson χ2 tests,
Mann–Whitney tests, or Kruskal–Wallis tests were used
to assess univariate associations of patient characteristics
with outcomes. Since there were few missing data re-
garding the MARS and BMQ, we conducted complete-
case analyses. However, information about the number
of medications and comorbidities could not be obtained
for all patients due to incompleteness of medical re-
cords. The potential factors found to be associated with
the outcomes at a significance level of p < 0.25 in uni-
variate analyses (Tables 2 and 3) were included in the
initial multivariate models. Two regression models were
built for both therapeutic groups. Due to collinearity, the
necessity–concern differential score was analyzed in a
separate model not including the necessity and concern
beliefs. Models with a higher R-squared value were then
selected. In the first model, binary logistic regression
with being adherent or non-adherent as the outcome
was conducted to obtain odds ratio (OR) with a 95%
confidence interval (CI) with manual backward elimina-
tion. In the second model, multinomial logistic regres-
sion with being adherent, unintentional non-adherent,
intentional non-adherent, and in part intentional non-
adherent as the outcomes was conducted to obtain OR
and 95% CI. All statistical analyses were carried out
using SPSS software (version 25.0; IBM, Armonk, NY,
USA).
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RESULTS
Baseline Characteristics
A total of 571 diabetes patients who were prescribed antihy-
pertensive drugs (492 patients) and/or antihyperlipidemic
drugs (245 patients) participated in this study (response rate
of 97.1%) from Bandung City (6 CHCs; 133 patients), Ma-
kassar City (3 CHCs; 67 patients), Samarinda City (5 CHCs;
162 patients), and Yogyakarta City (18 CHCs; 209 patients).
The mean values of MARS scores for those who were pre-
scribed antihypertensive and antihyperlipidemic drugs were
22.2 and 22.1, respectively (Table 1). Less than half of the
patients were male and most of patients were aged between 60
and 69 years and graduated from senior high school (Table 1).
Patients included in the analyses with antihypertensive drugs
had shorter diabetes duration than those in antihyperlipidemic
drug analysis. More than half of the patients who were pre-
scribed antihyperlipidemic drugs also received antihyperten-
sive drugs, while one-third of those who were prescribed
antihypertensive drugs received antihyperlipidemic drugs
(Table 1). The median scores of necessity beliefs and concern
beliefs were 15.0 (range 12.0–18.0) and 16.0 (range 12.0–
18.0) to antihypertensive drugs, and 14.0 (range 12.0–17.0)
and 16.0 (range 13.0–19.0) to antihyperlipidemic drugs,
respectively.
Around half of patients were non-adherent to antihyperten-
sive and to antihyperlipidemic drugs (45.5% and 52.7%, re-
spectively) (Table 2). Patients were further classified as unin-
tentional (14.4%, mean score 22.3), intentional (13.2%, mean
score 20.4), and in part intentional (17.9%, mean score 18.3)
Table 1 Patient Characteristics per Therapeutic Group
Characteristic Antihypertensive drugs (N = 492) Antihyperlipidemic drugs (N = 245)
Gender (%)
Male 181 (36.8) 72 (29.5)
Missing - 1 (0.4)
Age in years (%)
≤ 49 57 (11.6) 24 (9.8)
50–59 162 (32.9) 84 (34.3)
60–69 211 (42.9) 120 (49.0)
≥ 70 60 (12.2) 15 (6.1)
Missing 2 (0.4) 2 (0.8)
Type of insurance (%)
BPJS-PBI 76 (15.4) 40 (16.3)
BPJS-non PBI 349 (70.9) 143 (58.4)
Without insurance 14 (2.8) 13 (5.3)
Missing 53 (10.8) 49 (20.0)
Last education level (%)
No formal education/ elementary school 92 (18.7) 41 (16.7)
Junior high school 77 (15.7) 32 (13.1)
Senior high school 226 (45.9) 115 (46.9)
University 91 (18.5) 54 (22.0)
Missing 6 (1.2) 3 (1.2)
Time from diagnosis, mean (SD), years
Diabetes 4.7 (4.4) 4.9 (4.3)
Missing 75 (15.2) 49 (20.1)
Hypertension 4.4 (4.3) -
Missing 14 (2.8) -
Hyperlipidemia - 3.2 (3.2)
Missing - 34 (13.9)
Clinical data, mean (SD)
SBP (mmHg) 136.7 (13.9) -
Missing 9 (1.8) -
DBP (mmHg) 83.4 (8.1) -
Missing 9 (1.8) -
Total cholesterol level (mmol/L) - 223.5 (50.2)
Missing - 88 (35.9)
Specific co-medication
Antihyperlipidemic drug 166 (33.7) -
Antihypertensive drug - 166 (67.8)
Medication beliefs, median (IQR)
BMQ-necessity 15.0 (12.0–18.0) 14.0 (12.0–17.0)
Missing 1 (0.2) 1
BMQ-concern 16.0 (12.0–18.0) 16.0 (13.0–19.0)
Missing - 1
BMQ-side effects 2.0 (1.0–2.0) 2.0 (1.0–2.0)
Missing 1 (0.2) 1
Necessity–concern differential − 1.0 (– 3.0 to 3.0) − 1.0 (− 4.0 to 3.0)
Missing 1 (0.2) 1
MARS score, mean (SD) 22.2 (2.9) 22.1 (2.9)
Missing - 2 (0.8)
SD standard deviation, IQR interquartile range, BMQ Beliefs about Medicines Questionnaire, MARS Medication Adherence Report Scale, BPJS-PBI
insurance premium was paid by the government, BPJS-Non PBI insurance premium was paid by the patients themselves
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non-adherent to antihypertensive drugs, and as unintentional
(18.1%, mean score 22.6), intentional (6.6%, mean score
21.4), and in part intentional (28.0%, mean score 18.6) non-
adherent to antihyperlipidemic drugs (Table 3).
Factors Associated with Non-adherence to
Antihypertensive Drugs
From the univariate analyses, gender, age, last education level,
specific co-medication, necessity beliefs, concern beliefs, side
effects, and necessity–concern differential were selected as
potential factors associated with non-adherence (Table 2). In
the multivariate model, older age (60–69 years) (OR, 5.65;
95% CI, 2.68–11.92) was associated with non-adherence to
antihypertensive drugs, while higher necessity beliefs (OR,
0.92; 95% CI, 0.88–0.95) was associated with less non-
adherence (Table 4). The goodness-of-fit p value of this model
was .351 with an R-squared value of 15.2%. The model
including the necessity–concern differential had a lower R-
squared value of 12.7% (Table S1 in Supplementary data).
Similar patterns were seen for the subtypes of non-adherence.
Patients with higher necessity beliefs were less likely to be
unintentional (OR, 0.91; 95% CI, 0.86–0.97), intentional (OR,
0.93; 95%CI, 0.87–0.98), and in part intentional non-adherent
(OR, 0.92; 95% CI, 0.87–0.97) (Table 4). Patients aged 60–
69 years showed the highest odds of being unintentional,
intentional, and in part intentional non-adherent (Table 4).
Factors Associated with Non-adherence to
Antihyperlipidemic Drugs
From the univariate analyses, gender, age, type of insurance,
last education level, duration of hyperlipidemia, total choles-
terol level, specific co-medication, necessity beliefs, concern
beliefs, and necessity–concern differential were selected as
potential factors associated with non-adherence (Table 2). In
the multivariate model, significant factors associated with
non-adherence to antihyperlipidemic drugs were higher con-
cern beliefs (OR, 1.10; 95% CI, 1.03–1.18) and female gender
(OR, 1.84; 95% CI, 1.03–3.27), while higher necessity beliefs
(OR, 0.89; 95% CI, 0.83–0.96) was associated with less non-
adherence (Table 5). The goodness-of-fit p value of this model
Table 2 Univariate Associations with Non-adherent to Antihypertensive and/or Antihyperlipidemic Drugs
Characteristic Antihypertensive drugs (N = 492) Antihyperlipidemic drugs (N = 245)
Adherent Non-adherent p value Adherent Non-adherent p value
N (%) 268 (54.5) 224 (45.5) 115 (47.3) 128 (52.7)
MARS score, mean (SD) 23.9 (1.5) 20.2 (2.9) 24.0 (1.6) 20.3 (2.6)
Male gender (%) 105 (39.2) 76 (33.9) 0.229*,‡ 41 (35.7) 31 (24.4) 0.056*,‡
Age in years (%) 0.000*,‡ 0.010*,‡
≤ 49 47 (17.6) 10 (4.5) 15 (13.2) 9 (7.1)
50–59 105 (39.3) 57 (25.6) 48 (42.1) 34 (26.8)
60–69 86 (32.2) 125 (56.1) 45 (39.5) 75 (59.1)
≥ 70 29 (10.9) 31 (13.9) 6 (5.3) 9 (7.1)
Type of insurance (%) 0.766* 0.018*,‡
BPJS-PBI 47 (18.4) 29 (15.8) 18 (17.0) 22 (24.4)
BPJS-Non PBI 200 (78.4) 149 (81.0) 85 (80.2) 58 (64.4)
Without insurance 8 (3.1) 6 (3.3) 3 (2.8) 10 (11.1)
Last education level (%) 0.000*,‡ 0.028*,‡
Elementary school 41 (15.4) 51 (23.4) 13 (11.3) 28 (22.4)
Junior high school 33 (12.4) 44 (20.0) 18 (15.7) 14 (11.2)
Senior high school 146 (54.9) 80 (36.4) 63 (54.8) 51 (40.8)
University 46 (17.3) 45 (20.5) 21 (18.3) 32 (25.6)
Time since diagnosis, mean (SD), years
Diabetes 4.3 (3.7) 5.1 (5.0) 0.328† 4.7 (3.6) 5.0 (4.6) 0.493†
Hypertension 4.2 (3.8) 4.8 (4.8) 0.258† - -
Hyperlipidemia 3.4 (2.5) 3.0 (3.7) 0.001†,‡
Clinical data, mean (SD)
SBP (mmHg) 136.4 (12.6) 137.1 (15.4) 0.556† - - -
DBP (mmHg) 83.5 (6.9) 83.2 (9.3) 0.835† - - -
Total cholesterol level (mmol/L) - - - 233.0 (55.4) 217.8 (46.1) 0.112†,‡
Specific co-medication
Antihyperlipidemic drug 97 (36.2) 69 (30.8) 0.208*,‡ - - -
Antihypertensive drug - - - 92 (80.0) 74 (57.8) 0.000*,‡
Medication beliefs, median (IQR)
BMQ-necessity 15.0 (13.0–18.0) 13.0 (10.0–17.0) 0.000†,‡ 15.0 (13.0–18.0) 14.0 (11.3–16.0) 0.023†,‡
BMQ-concern 16.0 (13.0–18.0) 15.0 (10.0–18.0) 0.005†,‡ 16.0 (12.0–18.0) 17.0 (13.0–20.0) 0.044†,‡
BMQ-side effects 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.083†,‡ 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.325†
Necessity–concern differential 0 (− 3.0 to 4.0) − 1.0 (− 4.0 to 3.0) 0.036†,‡ 0 (− 2.0 to 4.0) − 2.0 (− 5.0 to 0) 0.000†,‡
*Pearson χ2 test
†Mann–Whitney test
‡Included in initial multivariate model
MARS Medication Adherence Report Scale, SD standard deviation, BPJS-PBI insurance premium was paid by the government, BPJS-Non PBI
insurance premium was paid by the patients themselves, SBP systolic blood pressure, DBP diastolic blood pressure, IQR interquartile range, BMQ
Beliefs about Medicines Questionnaire
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was .716 with an R-squared value of 9.1%. The model includ-
ing the necessity–concern differential had a lower R-squared
value of 6.6% (Table S2 in Supplementary data). Regarding
different subtypes of non-adherence, 1-year increase on the
duration of diabetes was associated with an increase in the
likelihood of intentional non-adherence (OR, 1.16; 95% CI,
1.04–1.30). Furthermore, patients with higher necessity beliefs
were less likely to be unintentional non-adherent (OR, 0.89;
95% CI, 0.80–0.98), and patients with higher concern beliefs
were more likely to be both unintentional (OR, 1.11; 95% CI,
1.01–1.22) and intentional (OR, 1.19; 95% CI, 1.03–1.37)
non-adherent (Table 5).
DISCUSSION
Around half of patients with type 2 diabetes being prescribed
antihypertensive or antihyperlipidemic drugs in our study
were non-adherent to this medication. Older age was associ-
ated with non-adherence to antihypertensive drugs, while
higher necessity beliefs were associated with less non-adher-
ence. Factors associated with non-adherence to
antihyperlipidemic drugs were higher concern beliefs and
female gender, while higher necessity beliefs were associated
with less non-adherence. In addition, longer duration of
diabetes was associated with intentional non-adherence to
antihyperlipidemic drugs.
We observed that patients with higher necessity beliefs were
less likely to be non-adherent to antihypertensive as well as to
antihyperlipidemic drugs. There were not much differences in
factors associated with the subtypes of non-adherence to anti-
hypertensive drugs indicating that necessity beliefs are rele-
vant for both unintentional and intentional non-adherence. In
patients with chronic diseases, perceived need may affect both
unintentional and intentional non-adherence, such that the
unintentional behavior may mediate intentional non-adher-
ence.19 A previous study among the general population in
Indonesia showed that the reason for intentional non-
adherence to antihypertensive drugs was a lack of necessity
beliefs, in such patients with asymptomatic conditions like
hypertension often perceive the need for medications to a
lesser extent.35 Our study showed that this is also the case in
patients with type 2 diabetes.
Furthermore, higher concern beliefs were associated with
non-adherence to antihyperlipidemic drugs. Similar results
were observed in subtypes of non-adherence to
antihyperlipidemic drugs, indicating that concern beliefs are
relevant for both unintentional and intentional non-adherence.
In contrast, concern beliefs were not associated with non-
adherence to antihypertensive drugs. Previous studies showed
Table 4 Factors Associated with Non-adherence and Different Subtypes of Non-adherence to Antihypertensive Drugs in Patients with Diabetes








non-adherence‡ (n = 88)
Age in years (n)
≤ 49 Reference Reference Reference Reference
50–59 2.37 (1.11–5.07) 1.72 (0.54–5.45) 7.52 (0.97–58.16) 1.82 (0.65–5.13)
60–69 5.65 (2.68–11.92) 4.17 (1.38–12.61) 15.59 (2.05–118.49) 4.59 (1.69–12.51)
≥ 70 4.14 (1.74–9.82) 2.24 (0.60–8.36) 15.81 (1.93–129.84) 3.10 (0.96–10.08)
BMQ-necessity 0.92 (0.88–0.95) 0.93 (0.87–0.98) 0.93 (0.88–0.99) 0.91 (0.86–0.96)
BMQ-concerns NA 0.94 (0.87–1.01) 0.98 (0.91–1.06) 1.04 (0.97–1.11)
*Final multivariate model
†Assessed by binary logistic regression with goodness-of-fit p value of non-adherence model, 0.351; R-squared, 15.2%
‡Assessed by multinomial logistic regression with adherent as a reference outcome group. Overall fit of the different subtypes of non-adherence model:
likelihood ratio chi-squared test, p < 0.05; pseudo R-squared, 14.7%
Table 5 Factors Associated with Non-adherence and Different Subtypes of Non-adherence to Antihyperlipidemic Drugs in Patients with
Diabetes
Factors Odds ratios* (95% CI)
Non-adherence† (n = 128) Unintentional
non-adherence‡ (n = 44)
Intentional
non-adherence‡ (n = 16)
In part intentional
non-adherence‡ (n = 68)
Female gender 1.84 (1.03–3.27) NA NA NA
Duration of diabetes (years) NA 1.02 (0.93–1.13) 1.16 (1.04–1.30) 1.01 (0.92–1.10)
BMQ-necessity 0.89 (0.83–0.96) 0.89 (0.80–0.98) 0.88 (0.76–1.02) 0.95 (0.87–1.04)
BMQ-concern 1.10 (1.03–1.18) 1.11 (1.01–1.22) 1.19 (1.03–1.37) 1.08 (0.99–1.17)
*Final multivariate model
†Assessed by binary logistic regression with goodness-of-fit p value of non-adherence model, 0.716; R-squared, 9.1%
‡Assessed by multinomial logistic regression with adherent as a reference outcome group. Overall fit of the different subtypes of non-adherence model:
likelihood ratio chi-squared test, p < 0.05; pseudo R-squared, 9.3%
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that concern beliefs may be important for adherence to
antihypertension, antihyperlipidemia, antidiabetic, asthma, os-
teoporosis, or depression.19 It could be that concerns regarding
antihyperlipidemic drugs are fueled by statin denialism or
skepticism but it is not known to what extend this is shared
in low- and middle-income countries. It is also possible that
more recent initiation of antihyperlipidemic drugs played a
role. New users to chronic medication more often become
intentionally non-adherent due to side effects and concerns
about medication.36 In our study, we did not know the time of
initiation but the duration of hyperlipidemia was on average
shorter than the duration of hypertension. Furthermore, differ-
ences in the prevalence of polypharmacy may have been
relevant. Polypharmacy is a known factor associated with
lower adherence in general.37, 38 Two-third of diabetes patients
who were prescribed antihyperlipidemic drugs were also using
antihypertensive drugs concurrently, whereas only one-third
of those who were prescribed antihypertensive drugs used
antihyperlipidemic drugs.
We found that older patients (> 49 years) were more likely
to be non-adherent to antihypertensive drugs compared with
younger patients, while no such association was found with
antihyperlipidemic drugs. It is possible that older patients in
our study may have experienced more side effects of antihy-
pertensive drugs compared to antihyperlipidemic drugs. On
the other hand, patients with longer duration of diabetes were
more l ike ly to be in t en t iona l non-adheren t to
antihyperlipidemic drugs, while no association was observed
with unintentional non-adherence nor with any type of non-
adherence to antihypertensive drugs. It could be that this
difference is influenced by different perceptions regarding
the long-term benefits of these drugs in patients with more
comorbidities.39 Finally, females were more likely to be non-
adherent to antihyperlipidemic drugs but this association was
lost in the analysis of subtypes of non-adherence. No associ-
ation was found between gender and non-adherence to anti-
hypertensive drugs. This is in line with conflicting results
regarding gender in previous studies.30, 40, 41 In general, it
seems that gender is not a very meaningful factor associated
with non-adherence.
Overall, most sociodemographic and clinical factors
were not associated with non-adherence to antihyperten-
sive or ant ihyperl ipidemic drugs in our study.
Sociodemographic factors, such as education level, may
be too general to predict an individual’s medication taking
behavior. This is in line with a previous study that showed
understanding the importance of treatment is more impor-
tant than the level of education.42 Using specific co-
medication was not associated with non-adherence either
to antihypertensive or antihyperlipidemic drugs. This find-
ing suggests that type of specific co-medication may be
not a relevant factor associated with non-adherence. Sur-
prisingly, side effects were not associated with non-
adherence in our study. One could expect, however, that
patients who experienced serious or frequent side effects
already stopped taking these drugs and therefore were not
included in our study.
The strength of this study is that we studied non-adherence
to antihypertensive and antihyperlipidemic drugs in the same
population, allowing us to study similarities and differences in
associated factors. In addition, by using the MARS question-
naire, we were able to make a distinction between uninten-
tional, intentional, and in part intentional non-adherence to
identify specific factors associated with different subtypes of
non-adherence. Furthermore, the high response rate observed
in this study makes the results generalizable for the Indonesian
population visiting CHCs for type 2 diabetes. This study was
conducted in different CHCs in different regions of Indonesia
which strengthens the generalizability of the study.
Some limitations need to be mentioned. Underestimating of
non-adherence may have occurred because self-reporting was
used for its assessment. Pill counts or pharmacy databases
would allow for an objective assessment of adherence but
such measures are not widely available in Indonesia. More-
over, pill counts and pharmacy databases cannot provide
information regarding the types of non-adherence (intentional
or unintentional). The MARS scale has been shown to corre-
late well with other indirect methods, including pill counts
among patients with hypertension and refill rates (using med-
ication possession ratio) among patients with stroke.43, 44
Furthermore, the subtype analyses sometimes included small
numbers leading to wide confidence intervals and loss of
power. Due to the cross-sectional design, no causal inferences
can be made regarding the temporal association between med-
ication beliefs and non-adherence. The overall association of
our models was relatively low, indicating that there are other
unmeasured factors that may influence non-adherence, for
example, the total number of medications used or having other
comorbidities.
CONCLUSIONS
Medication beliefs were a potentially modifiable factor asso-
ciated with non-adherence to antihypertensive as well as to
antihyperlipidemic drugs. In general, beliefs about the neces-
sity of the drug are important but for antihyperlipidemic drugs
concerns about the drug are important as well. Healthcare
providers should pay attention to identify and address medi-
cation beliefs during patient counselling.
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